Literature DB >> 308090

Cellular and molecular requirements for X-linked, hapten-specific B-cell blockade in CBA/N mice.

B Merchant, H Snippe, E F Lizzio, J K Inman.   

Abstract

CBA/N mice, a mutant CBA subline, harbor an X-linked B-cell defect which prevents them from mounting immune responses to certain thymic-independent antigens such as pneumococcal polysaccharides and haptenated-Ficoll derivatives. These mice and the hybrid male progeny of CBA/N females are also exquisitely sensitive to a hapten-specific blockade of their otherwise adequate immune responses to thymic-dependent antigens such as N-2,4-dinitrophenylated-hemocyanin (DNP-KLH). As little as 10 ng of a DNP-Ficoll conjugate given 2 h before immunization with a 5,000-fold greater dosage of DNP-KLH, virtually abolishes the 4th-day direct plaque-forming cell (PFC) response specific for DNP. Responding hybrid (CBA/N x C3H/HeN) female mice are resistant to such blockade even at DNP-Ficoll dosages increased by three orders of magnitude. The DNP hapten and Ficoll must be chemically joined for this blocking effect to occur, and increasing the hapten derivatization of Ficoll increases its blockade-invoking capacity. Significant blockade can be produced by administering DNP-Ficoll as early as 4 days before or as late as 4 h after immunization with DNP-KLH. All currently available data point to the defective B cell as the target of this hapten-polysaccharide-mediated blockade. Mice bearing B memory cells, however, are refractory to such blockade. In addition, DNP-Ficoll injections which cause virtually total blockade of 4th-day primary direct PFC responses to DNP-KLH have little or no effect on the development of DNP-reactive B-cell memory measured at either 8 or 30 days. These findings suggest very different blockade susceptibilities for B cells or their precursors at various stages of differentiative development. Our findings also lead to the formulation of testable hypotheses regarding the mechanism of this selective B-cell blockade phenomenon.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308090      PMCID: PMC2184319          DOI: 10.1084/jem.147.6.1755

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Evidence for the inactivation of precursor B cells in high dose unresponsiveness.

Authors:  C Desaymard; H Waldmann
Journal:  Nature       Date:  1976 Dec 23-30       Impact factor: 49.962

2.  B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens.

Authors:  A Ahmed; I Scher; S O Sharrow; A H Smith; W E Paul; D H Sachs; K W Sell
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

3.  X-linked genetic control of hapten-polysaccharide-mediated specific immune unresponsiveness in CBA/N mice.

Authors:  B Merchant; H Snippe; E F Lizzio; J K Inman
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

4.  The preparation and characterization of a thymic independent antigen: episilon-dinitrophenyl-L-lysine-Ficoll.

Authors:  P R McMaster; J D Owens; W E Vannier
Journal:  Immunochemistry       Date:  1977-03

5.  The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain.

Authors:  I Scher; M M Frantz; A D Steinberg
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

6.  Molecular determinants of immunogenicity: the immunon model of immune response.

Authors:  H M Dintzis; R Z Dintzis; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

7.  B cell tolerance induced by polymeric antigens. IV. Antigen-mediated inhibition of antibody-forming cells.

Authors:  G G Klaus
Journal:  Eur J Immunol       Date:  1976-03       Impact factor: 5.532

8.  B cell tolerance induced by polymeric antigens. II. Effects of tolerance on hapten-binding lymphocyte levels in primary and secondary antibody responses.

Authors:  G G Klaus
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

9.  B cell tolerance induced by polymeric antigens. I. Comparison of the dose and epitope density requirements for inactivation of primed and unprimed B cells in vivo.

Authors:  G G Klaus; J H Humphrey
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

10.  Role of epitope density in the induction of tolerance and immunity with thymus-independent antigens. III. Interaction of epitope density and receptor avidity.

Authors:  C Desaymard; B Pearce; M Feldmann
Journal:  Eur J Immunol       Date:  1976-09       Impact factor: 5.532

View more
  5 in total

1.  Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VII. Synergistic responses to haptenated liposomes and haptenated thymus-dependent antigens in CBA/N mice.

Authors:  H Snippe; A J Van Houte; A Janssen; E F Lizzio; J M Willers; B Merchant
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

2.  Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VI. Response in B-cell-defective CBA/N mice.

Authors:  H Snippe; A J van Houte; E F Lizzio; J M Willers; B Merchant
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

3.  Hapten-specific B cell blockade of the immune response to a thymus-independent-1 antigen produced by concomitant administration of a thymus-independent-2 antigen.

Authors:  H Snippe; A J Van Houte; J K Inman; E F Lizzio; B Merchant
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

4.  Immunoglobulin subclass-specific immunodeficiency in mice with an X-linked B-lymphocyte defect.

Authors:  R M Perlmutter; M Nahm; K E Stein; J Slack; I Zitron; W E Paul; J M Davie
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

Review 5.  The induction of hapten-specific immunological tolerance and immunity in B lymphocytes. VI. Differential tolerance susceptibility in adult spleen as a function of B-cell maturation level.

Authors:  J M Fidler
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.